Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients by Mark Eisenberg 22.06.2024 Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Avidity Biosciences Director Sells $3.8M in Stock by Mark Eisenberg 15.06.2024 Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
Protagenic’s PT00114 Breakthrough: New Hope for Stress Disorders by Mark Eisenberg 13.02.2024 Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...